Optimal Control of Cyclophosphamide-lnduced Emesis

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 32-38

  Stewart, A ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapys; Cyclophosphamide; Emesis; Ondansetron

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOMPERIDONE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; METHYLPREDNISOLONE; METOCLOPRAMIDE; ONDANSETRON; PHENOTHIAZINE; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; THIETHYLPERAZINE;

ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HUMANS; LOMUSTINE; METHOTREXATE; PROCARBAZINE; RANDOMIZED CONTROLLED TRIALS; VOMITING;

EID: 0029789420     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227638     Document Type: Article

References (38)

1. Martin M: The severity and pattern of emesis following different cytotoxic agents, Oncology 1996;53(suppl l):26-31.
2. David M, Durand M, Chauvergne J, Mauriac L, Bui BN, Hoemi B: Cyclophosphamide, methotrexate and 5-FU (CMF)-induccd nausea and vomiting: A controlled study with high-dose metoclopramide, Cancer Treat Rep 1984: 68:921-922.
3. Beck TM: Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: Review of clinical trials, Semin Oncol 1992;(suppl 15):20-25.
4. Fctting JH, Grochow LB, Folstein MF, Ettin-ger DS, Colvin M: The course of nausea and vomiting after high-dose cyclophosphamide CancerTrcat Rep 1982:66:1487-1493
5. Morran C, Smith DC, Anderson DA, McArdlc CS: Incidence of nausea and vomiting witli cytotoxic chemotherapy: A prospective randomised trial of antiemetics, Br Med J 1979:1: 1323-1324.
6. Jantunen IT, Muhonen TT, Kataja VV, Flan-der MK, Teerenhovi L: 5-HT-, receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - A randomised study, Eur J Cancer 1993: 29A: 1669-1672.
7. Marty M: A comparative study of the use ol granisetron, a selective 5-1 IT; antagonist, versus a standard anti-emetic regimen of chlor-promazine plus dexamethasone in the treatment of cytostatic-induced emesis, Eur J Cancer 1990;26(suppl 1):S28-S32.
8. Jones AL, Hill AS, Soukop M, Hutchcon AW Cassidy J, Kaye S, Sikora K, Carney DN, Cunningham D: Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy, Lancet 1991:24:483-487.
9. Warr D, Willan A, Fine S, Wilson K, Davis A Erlichman C, Rusthoven J, Lofters D, Osoba D, Labcrge F, Latreille J, Pater J: Superiority ol granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis, J Natl Cancer Inst 1991:83: 1169-1173.
10. Vogt C, Ilellenbrecht D, Sailer R, Achtert G Brockmann P, Hausleiter H: Oral medium-dosed metoclopramide versus placebo as higlilv effective antienictic prophylaxis in in- and outpatients on noncisplatin chemotherapy, Oncology 1993:50:81-85.
11. Buser KS, Joss RA, Piquet D, Aapro MS, Ca-valli F, Haefliger JM, Jungi WF, Baur J, Obrist R, Brunner KW, Weber T, Verity L, Butcher M: Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer, Results of a prospective, randomized, double-blind placebo-controlled study, Ann Oncol 1993;4:475-479.
12. Levitt M, Warr D, Yelle L, Ravner HL, Lofters WS, Perrault DJ, Wilson KS, Latreille J, Ptvin M, Warner E, Pritchard K, Palmer M, Zee B, Prater JL: Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate and fluoroura-cil, N Engl J Med 1993;328:1081-1084.
13. Wilcox PM, Fctting JH, Nettesheim M, Abe-loff MD: Anticipatory vomiting in women receiving cyclophosphamide, methotrexate and 5-FU (CMF) adjuvant chemotherapy for breast cancer, Cancer Treat Rep 1982;66:1601-1604.
14. Beck TM, Ciociola AA, Jones SE, Harvcv WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cy-clophosphamide-based chemotherapy, Ann Intern Med 1993:118:407-413.
15. Cubeddu LX, Pendergrass K, Rvan T, York M, Burton G, Meshad M, Galvin D, Ciociola AA, and the Ondansetron Study Group: Efficacy of oral ondansetron, a selective antagonist of 5-HT; receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies, Am J Clin Oncol 1994: 17:137-146.
16. Beck TM: The pattern of emesis following high-dose cyclophosphamide and the antiemetic efficacy of ondansetron, Anticancer Drugs 1995:6:237-242.
17. Roila F, Basurto C, Minotti V, Ballalori E, Tonato M, Del Favero A: Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: A double-blind randomized study, Oncology 1988:45:346-349.
18. Campora E, Chiara S, Bruzzi P, Rosso R: The anliemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: A randomized trial, Tumori 1985:71:459-462.
19. Pollcra CF, Nardi M, Marolla P, Pinnaro P, Tcrzoli E, Giannarelli D: Effective control of CMF-related emesis with high-dose dexamcth-asone: Results of a double-blind crossover trial with metoclopramide and placebo, Am J Clin Oncol 1989:12:524-529.
20. Roila F, Tonato M, Basurto C, Minotti V, Bal-latori E, Del Favero A: Double-blind controlled trial of antiemetic efficacy and toxicity of methylprednisolone, metoclopramide and dompcridone in breast cancer patients treated with i.v, CMF, Eur J Cancer Clin Oncol 1987: 23:615-617.
21. Getz E, Strauss N, Vitzhaka N, Cass Y, Zvi Edelmann D: Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide methotrexate and 5-fiuo-rouracil: A prospective, crossover, randomised blind study comparing two different dose schedules, Cancer Chemother Pharmacol 1992;30:229-232.
22. Chiara S, Campora E, Lionetto R, Bruzzi P, Rosso R: Methylprednisolone for the control of CMF-induced emesis, Am J Clin Oncol 1987: 10:264-267.
23. Campora E, Oliva C, Mammolitis S, Cctto GL, Fosscr V, Marangoio M, Rosso R: Oral ondansetron (GR38032F) for the control of CMF-induccd emesis in the outpatient Breast Cancer Res Treat 1991:19:129-132.
24. Soukop M, McQuadc B, Hunter E, Stewart A, Kave S, Cassidy J, Kerr D, Khanna S, Smyth J, Coleman R, Cunningham D, Powles T, Davidson N, Hutchcon A, Green J, Slater A, Rustin G, Carney D: Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer, Oncology 1992;49:295-304.
25. Gralla RJ, Tyson LB, Bordin LA, Clark RA, Kelsen DP, Kris MG, Kalman LB, Groshcn S: Anticmetic therapy: A review of recent studies and a report of a random assignment trial comparing mctoclopramide with dclta-9-tetrahy-drocannabinol, Cancer Treat Rep 1984;68: 163-172.
26. Edge SB, Funkhouser WK, Berman A, Scipp C, Tanner A, Wesley R, Rosenberg SA, Chang AE: High-dose oral and intravenous mctoclopra-midc in doxorubicin/cyclophosphamidc-in-dueed emesis, Am J Clin Oncol 1987;10:257-263.
27. Diaz-Rubin E, Martin M, Rosell R, Valcrdi JJ, Gonzalez-L’Arriba JL, Barriga JJ: The anti-emctic cfTicacy of thicthvlperazine and mcthyl-prcdnisolone versus thiethylpcrazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide), Acta Oncol 1991; 30:339-342.
28. Martin M, Diaz-Rubio E, Casado A, Dominguez S, Sastre J: Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy, Eur J Cancer 1992:28:430-432.
29. Kaasa S, Kvalov S, Dicato MA, Ries F, Huy JV, Roger E, Carruthcrs L: A comparison of ondansetron with metociopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study, Eur J Cancer 1990:26:311-314.
30. Marschner NW, Adler M, Nagel GA, Christ-mann D, Fenzl E, Upadhyaya B: Double-blind randomized trial of the anti-emetic efficacy and safety of ondansetron and metociopramide in advanced breast cancer patients treated with cpirubicin and cyclophosphamide, Eur J Canccr 1991:27:1137-1140.
31. Bonnctcrre J, Chcvallicr B, Metz R, Fargcot P, Pujadc-Laurainc E, Spiclmann M, Tubiana-Hulin M, Paes D, Bons J: A randomized double-blind comparison of ondansetron and metociopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or cpirubicin chemotherapy, J Clin Oncol 1990:8:1063-1069.
32. Schmoll HJ: The role of ondansetron in the treatment of emesis induced by non-cisplatin containing chemotherapy regimens, Eur J Cancer Clin Oncol 1989:25(suppl 1):S35-S39.
33. Dicato MA, Kaasa S, Campora E, Bleibcrg H, Warnier P, Vindcvoghel A, Cunningham D, Iibhard A, Upadhyaya BK, and the Ondansetron International Study Group: Efficacy of twice daily versus three times a day oral ondansetron in the prevention of chemothcrapv-induced emesis: A randomised, single-blind study, Clin Oncol 1992:4:275-279.
34. Bonnctcrre J, Clavcl M: Comparison between ondansetron tablet and alizapride injection in the prevention of emesis induced by cytotoxic regimens in breast cancer patients, Ann Oncol 1992:3:183, abstr699.
35. Campora E, Giudici S, Mcrlini L, Rosso R: Control of acute and delayed FEC/FAC-in-duccd cmesis and GI toxicity at subsequent cycles: A randomised trial of mctoclopramidc, dcxamcthasone and orphenadrinc versus ondansetron and dcxamcthasone, Proc Am Soc Clin Oncol 1992; 11, abslr 1358.
36. Roberts JT, Priestman TJ: A review of ondansetron in the management of radiotherapy-induced cmesis, Oncology 1993;50:173-179.
37. Roilf, F, Tonato M, Cognetti F, Cortcsi E, Fa-valli G, Marangolo M, Amadori D, Bella MA, Gramazro V, Donati D, Ballatri E, Del Favcro A: Prevention of cisplatin-induced emesis: A double-blind multiccntrc randomised crossoverstudy comparing ondansetron and ondansetron plus dexamethasone, J Clin Oncol 1991; 9:675-678.
38. Smyth JF, Coleman RE, Nicolson M, Gall-meier WM, Leonard RCF, Combleet MA, Allan SG, Upadhyaya BK, Bruntsch U: Does dexamethasone enhance control of acute cisplatin-induced emesis by ondansetron? Br J Med 1991:303:1423-1426.